陈万青, 郑荣寿, 张思维. 中国恶性肿瘤的动态变化[J]. 科技导报, 2014, 32(26): 65-71. [2]Warburg O. On the origin of cancer cells[J]. Science, 1956, 123(3191): 309-314. [3]Shinohara Y, Yamamoto K, Kogure K, et al. Steady state transcript levels of the type Ⅱ hexokinase and type 1 glucose transporter in human tumor cell lines[J]. Cancer Lett, 1994, 82(1): 27-32. [4]Meng M B, Wang H H, Guo W H, et al. Targeting pyruvate kinase M2 contributes to radiosensitivity of non-small cell lung cancer cells in vitro and in vivo[J]. Cancer Lett, 2015, 356(2 Pt B): 985-993. [5]刘博宁, 罗猛, 周清华, 等. 糖酵解与肺癌相关研究进展[J]. 中国肺癌杂志, 2012, 15(4): 228-233. [6]Parada L F, Weinberg R A. Presence of a Kirsten murine sarcoma virus ras oncogene in cells transformed by 3-methylcholanthrene[J]. Mol Cell Biol, 1983, 3(12): 2298- 2301. [7]Kinnaird A, Michelakis E D. Metabolic modulation of cancer: a new frontier with great translational potential[J]. J Mol Med (Berl), 2015, 93(2): 127-142. [8]梁丽峰, 李佩佩, 常蕊静, 等. 人小细胞肺癌细胞H446及其MDR细胞H446/DDP受顺铂冲击后乳酸代谢与活性氧产生情况[J]. 中华肺部疾病杂志: 电子版, 2013, 6(2): 134-138. [9]Levine A J, Puzio-Kuter A M. The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes[J]. Science, 2010, 330(6009): 1340-1344. [10]Bryant K L, Mancias J D, Kimmelman A C, et al. KRAS: feeding pancreatic cancer proliferation[J]. Trends Biochem Sci, 2014, 39(2): 91-100. [11]Sasaki H, Shitara M, Yokota K, et al. Overexpression of GLUT1 correlates with Kras mutations in lung carcinomas[J]. Mol Med Rep, 2012, 5(3): 599-602. [12]Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web[J]. Nat Rev Cancer, 2011, 11(11): 761-774. [13]Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation[J]. Nature, 2008, 454(7203): 436-444. [14]Leibovich-Rivkin T, Liubomirski Y, Meshel T, et al. The inflammatory cytokine TNFα cooperates with Ras in elevating metastasis and turns WT-Ras to a tumor-promoting entity in MCF-7 cells[J]. BMC Cancer, 2014, 14: 158. [15]徐采云, 李理, 袁伟锋, 等. 不同浓度肿瘤坏死因子-α对肺腺癌A549细胞的影响[J]. 山东医药, 2013, 53(21): 4-6.
[2]
谢燕,喻秀丽,童立纺.硼替佐米对A549细胞增殖及p21、p27表达的影响[J].第三军医大学学报,2012,34(17):1775. Xie Yan,Yu Xiuli,Tong Lifang.Anti-proliferation effect of proteasome inhibitor bortezomib in human lung adenocarcinoma A549 cells[J].J Third Mil Med Univ,2012,34(11):1775. [2]王孟昭,张紫萱.肺癌的靶向治疗[J].第三军医大学学报,2012,34(20):2035. Wang Mengzhao,Zhang Zixuan.Target therapy in lung cancer[J].J Third Mil Med Univ,2012,34(11):2035. [3]莫贵艳,李敏,胡成平,等.茶氨酸对内皮细胞生长及肺癌血管生成的影响[J].第三军医大学学报,2012,34(20):2043. Mo Guiyan,Li Min,Hu Chengping,et al.Theanine suppresses angiogenesis of endothelial cells in vitro and in vivo[J].J Third Mil Med Univ,2012,34(11):2043. [4]刘晓丽,马礼鸿,王全义,等.XIAP、c-jun在肺癌组织中的表达及其意义[J].第三军医大学学报,2012,34(23):2408. Liu Xiaoli,Ma Lihong,Wang Quanyi,et al.Expression and clinical significance of XIAP and c-jun in human lung cancer tissues[J].J Third Mil Med Univ,2012,34(11):2408. [5]李长毅,张明川,梅同华,等.持续小剂量化疗对A549肺癌PTEN基因和凋亡的影响[J].第三军医大学学报,2007,29(18):1760. LI Chang-yi,ZHANG Ming-chuan,MEI Tong-hua,et al.Low-dose metronomic chemotherapy upregulates PTEN and induces apoptosis of A549 pulmonary adenocarcinoma in athymic mice[J].J Third Mil Med Univ,2007,29(11):1760. [6]邓丽平,董文,杜艳萍,等.支气管肺泡灌洗液和血清肿瘤标志物联合检测在肺癌诊断中的价值[J].第三军医大学学报,2008,30(01):78. DENG Li-ping,DONG Wen,DU Yan-ping,et al.Combined determination of tumor markers in serum and bronchoalveolar lavage fluid for lung cancer diagnosis[J].J Third Mil Med Univ,2008,30(11):78. [7]李代蓉,周清华,郭占林,等.CYP2E1基因多态性与肺癌遗传易感性的关系[J].第三军医大学学报,2008,30(13):1231. LI Dai-rong,ZHOU Qing-hua,GUO Zhan-lin,et al.Association between genetic polymorphisms of CYP2E1 and lung cancer susceptibility: a case control study[J].J Third Mil Med Univ,2008,30(11):1231. [8]李艳秋,李建春,关洪全,等.肺癌患者外周血Th1/Th2细胞因子及IL-18水平变化与肿瘤分期的关系[J].第三军医大学学报,2007,29(08):731. LI Yan-qiu,LI Jian-chun,GUAN Hong-quan,et al.Changes of IL-18 and Th1/Th2 in serum of lung cancer patients and their relationship with tumor staging[J].J Third Mil Med Univ,2007,29(11):731. [9]戴纪刚,肖颖彬,闵家新,等.非小细胞肺癌线粒体基因组大片段缺失突变研究[J].第三军医大学学报,2006,28(21):2123. [10]王红梅,廖国清,雷红,等.晚期肺癌患者肺部感染病原学分析[J].第三军医大学学报,2006,28(20):2103.
